Article
Single-cell sequencing demonstrates complex resistance landscape in CLL and MCL treated with BTK and BCL2 inhibitors.
Blood advances - 25 Jan 2022
Thompson Ella R, Nguyen Tamia, Kankanige Yamuna, Markham John F, Anderson Mary Ann, Handunnetti Sasanka M, Thijssen Rachel, Yeh Paul Sung-Hao, Tam Constantine S, Seymour John F, Roberts Andrew W, Westerman David A, Blombery Piers
Abstract excerpt
The genomic landscape of resistance to targeted agents (TAs) used as monotherapy in chronic lymphocytic leukemia (CLL) is complex and often heterogeneous at the patient level. To gain insight into the clonal architecture of acquired genomic resistance to Bruton tyrosine kinase (BTK) inhibitors and B-cell lymphoma 2 (BCL2) inhibitors in CLL, particularly in patients carrying multiple resistance mutations, we...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.